KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Work In Process: 2022-2025

Historic Work In Process for Sarepta Therapeutics (SRPT) over the last 2 years, with Sep 2025 value amounting to $885.4 million.

  • Sarepta Therapeutics' Work In Process rose 83.63% to $885.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $885.4 million, marking a year-over-year increase of 83.63%. This contributed to the annual value of $610.7 million for FY2024, which is 91.77% up from last year.
  • Sarepta Therapeutics' Work In Process amounted to $885.4 million in Q3 2025, which was up 10.28% from $802.9 million recorded in Q2 2025.
  • Sarepta Therapeutics' Work In Process' 5-year high stood at $885.4 million during Q3 2025, with a 5-year trough of $269.2 million in Q4 2022.
  • Over the past 3 years, Sarepta Therapeutics' median Work In Process value was $610.7 million (recorded in 2024), while the average stood at $618.9 million.
  • Data for Sarepta Therapeutics' Work In Process shows a peak YoY spiked of 91.77% (in 2024) over the last 5 years.
  • Quarterly analysis of 4 years shows Sarepta Therapeutics' Work In Process stood at $269.2 million in 2022, then grew by 18.30% to $318.5 million in 2023, then spiked by 91.77% to $610.7 million in 2024, then soared by 83.63% to $885.4 million in 2025.
  • Its Work In Process was $885.4 million in Q3 2025, compared to $802.9 million in Q2 2025 and $762.2 million in Q1 2025.